Oculis Holding AG (OCS) Exchange Rate Effect (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Exchange Rate Effect of $619347.3 for Q1 2026, up 146.48% year-over-year from $251275.9 in Q1 2025, and up 6287.68% quarter-over-quarter from -$10009.4 in Q4 2025.
Oculis Holding AG (OCS) Exchange Rate Effect (2022 - 2026) Analysis & Trends
Oculis Holding AG's Exchange Rate Effect history runs 5 years deep, the most recent figure standing at $619347.3 for Q1 2026.
- In Q1 2026, Exchange Rate Effect rose 146.48% year-over-year to $619347.3; the TTM figure through Mar 2026 stood at -$5.3 million (down 147.62% YoY), while the FY2025 annual figure was -$7.3 million, down 1679.62% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at $619347.3, up from -$10009.4 in the prior quarter.
- The five-year high for Exchange Rate Effect was $4.7 million in Q3 2023, with the low at -$5.7 million in Q2 2025.
- The 5-year median for Exchange Rate Effect is -$327314.9 (2024), against an average of -$640262.8.
- The sharpest annual moves came in 2023 and 2025: Exchange Rate Effect soared 1878.16% in 2023, then slumped 1653.63% in 2025.
- Oculis Holding AG's Exchange Rate Effect stood at -$446349.4 in 2022, then slumped by 291.23% to -$1.7 million in 2023, then soared by 154.98% to $960019.9 in 2024, then plunged by 101.04% to -$10009.4 in 2025, then surged by 6287.68% to $619347.3 in 2026.
- Business Quant data shows OCS's Exchange Rate Effect at $619347.3 in Q1 2026, -$10009.4 in Q4 2025, and -$126261.1 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 907,176.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 907,176.44 |
| Jun 30, 2026 | 907,176.44 |
| Mar 31, 2026 | 619,347.27 |
| Mar 31, 2026 | 619,347.27 |
| Dec 31, 2025 | -10,009.36 |
| Dec 31, 2025 | -10,009.36 |
| Sep 30, 2025 | -126,261.06 |
| Sep 30, 2025 | -126,261.06 |
| Jun 30, 2025 | -5.74 Mn |
| Jun 30, 2025 | -5.74 Mn |
| Mar 31, 2025 | -1.33 Mn |
| Mar 31, 2025 | -1.33 Mn |
| Dec 31, 2024 | 960,019.87 |
| Dec 31, 2024 | 960,019.87 |
| Sep 30, 2024 | -1.42 Mn |
| Sep 30, 2024 | -1.42 Mn |
| Jun 30, 2024 | -327,314.87 |
| Jun 30, 2024 | -327,314.87 |
| Mar 31, 2024 | 1.25 Mn |
| Mar 31, 2024 | 1.25 Mn |